Key insights
- Hologic's acquisition by Blackstone and TPG for $76/share + contingent value rights is complete, taking the company private. While the deal itself removes HOLX from the public market, downward earnings revisions by analysts suggest potential headwinds for the healthcare sector, contributing to a slightly bearish signal.
MARLBOROUGH, Mass. - Hologic Inc. (NASDAQ:HOLX) completed its acquisition by funds managed by Blackstone and TPG today, transitioning the women’s health company to private ownership in a transaction valued at up to $79 per share, according to a press release statement.
The deal includes minority investments from a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC. Joe Almeida was appointed Chief Executive Officer effective immediately, replacing Stephen MacMillan, who retired after more than 12 years leading the company.
The transaction was announced on October 21, 2025, and received approval from Hologic stockholders on February 5, 2026. Stockholders will receive $76 per share in cash plus a non-tradable contingent value right to receive up to $3 per share in two payments of up to $1.50 each. The contingent payments depend on achieving certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.The stock closed at $76.01, trading near its 52-week high of $76.07, reflecting the market’s confidence in the deal’s completion. With a market capitalization of $16.97 billion and revenue of $4.13 billion over the last twelve months, Hologic maintained a strong financial profile heading into private ownership, including a gross profit margin of 60% and a current ratio above 4.
Almeida previously served as Chairman, President and Chief Executive Officer of Baxter International Inc. from 2016 to early 2025. Before that, he was Chairman, President and CEO of Covidien plc until its acquisition by Medtronic in 2015. He holds a Bachelor of Science in mechanical engineering from Instituto Mauá de Tecnologia in São Paulo, Brazil.According to InvestingPro, which assigned Hologic a "GREAT" financial health score, the company was trading near its 52-week high as the deal closed, though 6 analysts had revised earnings downwards for upcoming periods. For investors seeking deeper insights into healthcare sector transitions, InvestingPro offers comprehensive Pro Research Reports covering over 1,400 US equities, transforming complex data into actionable intelligence.
Hologic’s common stock has ceased trading and will be delisted from the Nasdaq Stock Market.
Blackstone manages $1.3 trillion in assets under management across various investment strategies. TPG has $303 billion of assets under management and invests across private equity, impact, credit, real estate and market solutions.
In other recent news, Hologic, Inc. reported fiscal first-quarter earnings that did not meet analyst expectations. The company posted revenue of $1.05 billion, which was below the consensus estimate of $1.07 billion, and adjusted earnings per share of $1.04, missing the forecasted $1.09. Additionally, Hologic announced a significant corporate development as Steve MacMillan will retire from his roles as Chairman, President, and CEO when the company’s acquisition by Blackstone and TPG concludes. The acquisition has received all necessary regulatory approvals and is anticipated to close shortly.
In regulatory developments, Hologic’s Aptima HPV Assay received FDA approval for primary screening, enhancing the company’s cervical cancer screening portfolio. This assay is notable for being the only FDA-approved mRNA-based HPV test aimed at detecting infections most likely to result in cervical cancer. These recent developments highlight a period of transition and regulatory progress for Hologic.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.